Thermo Fisher ScientificTMO
About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Employees: 125,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
14% more funds holding in top 10
Funds holding in top 10: 72 [Q4 2024] → 82 (+10) [Q1 2025]
2% more repeat investments, than reductions
Existing positions increased: 1,004 | Existing positions reduced: 981
0.96% less ownership
Funds ownership: 88.16% [Q4 2024] → 87.21% (-0.96%) [Q1 2025]
3% less first-time investments, than exits
New positions opened: 148 | Existing positions closed: 153
3% less funds holding
Funds holding: 2,565 [Q4 2024] → 2,497 (-68) [Q1 2025]
7% less capital invested
Capital invested by funds: $177B [Q4 2024] → $164B (-$13.2B) [Q1 2025]
11% less call options, than puts
Call options by funds: $961M | Put options by funds: $1.08B
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
Argus Research David Toung | 19%upside $470 | Buy Maintained | 29 Apr 2025 |
Scotiabank Sung Ji Nam | 53%upside $605 | Sector Perform Maintained | 25 Apr 2025 |
RBC Capital Conor McNamara | 61%upside $637 | Outperform Maintained | 24 Apr 2025 |
UBS Dan Leonard | 26%upside $500 | Buy Maintained | 24 Apr 2025 |
Stifel Daniel Arias | 56%upside $620 | Buy Maintained | 24 Apr 2025 |
Financial journalist opinion
Based on 21 articles about TMO published over the past 30 days









